Cloud-based version of StarDrop retains all the functionality and interactivity of desktop version with improved accessibility and lower total cost of ownership for customers Optibrium recently received ISO 27001 accreditation for its information security system CAMBRIDGE, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced that its drug […]

Cambridge, UK – Cresset, an innovative provider of solutions for computer-aided drug design (CADD), design-make-test-analyze (DMTA) efficiency, and drug discovery contract research has been accepted onto the Innovate UK Scaleup Programme, which aims to help specially selected businesses with scaling potential realise their commercial ambitions. From its headquarters in Cambridge, UK, Cresset has ambitious plans to scaleup its […]

Backed by six years’ research, the new StarDrop Metabolism module combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates The module launches within a larger StarDrop update, which also sees additional features, including high-performance 3D virtual screening capabilities available on desktop CAMBRIDGE, UK – Optibrium, a leading developer of software […]

Cambridge, UK – Torx® Software Limited announces a collaboration with CDD Vault to facilitate the seamless synthesis and registration of new compounds during the small-molecule drug discovery process. Torx, is a cloud-based platform developed by Cresset and Elixir™ Software which enables chemistry teams to collaborate, design molecules and track compound synthesis across the design-make-test-analyze (DMTA) […]

BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as Vice Presidents in the newly-created BioPharmics Division CAMBRIDGE, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades […]

Version 2023 of the Classic pKa calculator in Percepta® includes a significantly expanded training set for improved prediction accuracy, broader chemical applicability, and algorithmic changes that deliver impressive speed enhancements to this industry-leading software. San Francisco, US —26 years after the release of their first ionization predictor, ACD/Labs, an informatics company that develops and commercializes software in support […]

Cambridge, UK – Torx ® Software Limited, announces the release of Torx 2.0, extending the platform’s scientific reach and capabilities to deliver unrivalled seamless integration across the drug discovery Design-Make-Test-Analyze (DMTA) cycle. Torx is a visual, chemistry aware, cloud-native platform. By enabling chemistry teams to design molecules, track compound synthesis from start to finish and […]

We are excited to announce our partnership with EDB, the leading provider of Postgres-based data management solutions. Our collaboration brings together EDB Postgres Advanced Server and Chemaxon’s JChem PostgreSQL Cartridge to offer customers a comprehensive and seamless solution for chemical structure searching and management. The certificate opens up new possibilities for our users by integrating our […]

Appointment will lead research strategy to apply the latest scientific innovations to Optibrium’s computational and AI drug discovery technologies Hamed brings extensive computational engineering and design experience from industry leader, Illumina CAMBRIDGE, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Dr Hamed Tabatabaei Ghomi as […]

The collaboration will connect PostEra’s synthesis prediction technology with Optibrium’s comprehensive platform for design, optimisation and data analysis for small molecule discovery CAMBRIDGE, UK and BOSTON, USA – Optibrium, a leading developer of software and AI for small molecule discovery, and PostEra, an AI-first biotechnology company with advanced machine learning (ML) technology for preclinical discovery, today […]